Here, we demonstrate that PKCδ inhibition first decreased the expression of BMI1, which is crucial for the self-renewal of LSCs, and subsequently sensitized both proliferative and primary CML CD34+ cells to all the clinically available TKIs. The gene discussed is BMI1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.